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SUMMARY 9 
Background: Observational studies have suggested that accelerated surgery is associated with 10 
improved outcomes in patients with a hip fracture.  The HIP ATTACK trial assessed whether 11 
accelerated surgery could reduce mortality and major complications.   12 
Methods: We randomised 2970 patients from 69 hospitals in 17 countries.  Patients with a hip 13 
fracture that required surgery and were ≥45 years of age were eligible.  Patients were randomly 14 
assigned to accelerated surgery (goal of surgery within 6 hours of diagnosis; 1487 patients) or 15 
standard care (1483 patients).  The co-primary outcomes were 1.) mortality, and 2.) a composite 16 
of major complications (i.e., mortality and non-fatal myocardial infarction, stroke, venous 17 
thromboembolism, sepsis, pneumonia, life-threatening bleeding, and major bleeding) at 90 days 18 
after randomisation.  Outcome adjudicators were masked to treatment allocation, and patients 19 
were analysed according to the intention-to-treat principle; ClinicalTrials.gov, NCT02027896.  20 
Findings: The median time from hip fracture diagnosis to surgery was 6 hours (interquartile 21 
range [IQR] 4-9) in the accelerated-surgery group and 24 hours (IQR 10-42) in the standard-care 22 
group, p<0.0001.  Death occurred in 140 patients (9%) assigned to accelerated surgery and 154 23 
patients (10%) assigned to standard care; hazard ratio (HR) 0.91, 95% CI 0.72-1.14; absolute risk 24 
reduction (ARR) 1%, 95% CI -1-3%; p=0.40.  The primary composite outcome occurred in 321 25 
patients (22%) randomised to accelerated surgery and 331 patients (22%) randomised to standard 26 
care; HR 0.97, 95% CI 0.83-1.13; ARR 1%, 95% CI -2-3%; p=0.71.    27 
 Interpretation: Among patients with a hip fracture, accelerated surgery did not significantly 28 
lower the risk of mortality or a composite of major complications compared to standard care.   29 
Funding: Canadian Institutes of Health Research. 30 
 31 
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INTRODUCTION 32 
 Worldwide, >1.5 million adults suffer a hip fracture each year.1  Non-surgical 33 
management of a hip fracture is associated with a low probability of remaining ambulatory and 34 
an increased risk of chronic pain and mortality.2,3  In high-income countries, approximately 95% 35 
of hip fractures are managed surgically.4,5  Patients undergoing hip fracture surgery have higher 36 
risk-adjusted mortality and major complications than patients undergoing elective total hip 37 
replacement surgery, suggesting hip fractures, independent of surgery, increase patients’ risks.6    38 
Patients who suffer a hip fracture are at substantial risk of major complications (i.e., 39 
cardiovascular, infectious, bleeding, and neuro-cognitive) and mortality.7-9  Observational studies 40 
suggest that accelerated surgery for a hip fracture is associated with a lower risk of mortality and 41 
major complications.10,11  Hip fractures result in pain, bleeding, and immobility, and activate 42 
inflammatory, hypercoagulable, catabolic, and stress states that can precipitate medical 43 
complications.12-15  Accelerated surgery will reduce the time patients are exposed to these 44 
harmful states and therefore may reduce the risk of medical complications and mortality.  We 45 
undertook the HIP fracture Accelerated surgical TreaTment And Care tracK (HIP ATTACK) trial 46 
to determine whether accelerated surgery for hip fracture was superior to standard care in 47 
reducing death or other major complications.   48 
 49 
METHODS 50 
Study design, patients, and patient engagement 51 
 We undertook this investigator-initiated, randomised, controlled trial at 69 hospitals in 17 52 
countries (i.e., Canada, Spain, India, Pakistan, South Africa, Italy, Poland, United Kingdom, 53 
United States, Malaysia, Belgium, France, Thailand, Netherlands, China, Hong Kong, 54 
Colombia).  We have previously reported details of the trial design and methods.16,17  Study 55 
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personnel recruited patients from March 14, 2014 to May 24, 2019.  Before commencing 56 
recruitment, all centres obtained ethics approval, and the relevant health authorities approved the 57 
protocol.   58 
Eligible patients were ≥45 years of age and diagnosed during regular working hours with 59 
a low-energy mechanism hip fracture that required surgery.  Centres defined their study hours 60 
based on the local regular working hours.  We excluded patients taking a therapeutic-dose of an 61 
anticoagulant for which no reversing agent was available, with a history of heparin induced 62 
thrombocytopenia if they were taking a therapeutic-dose vitamin K antagonist, with a peri-63 
prosthetic or open fracture, with bilateral fractures, requiring an emergency surgery for another 64 
reason (e.g., subdural hematoma), refusing consent, or previously enrolled in HIP ATTACK.     65 
Our approach to patient engagement was guided by the Canadian Institutes of Health 66 
Research (CIHR) Strategy for Patient-Oriented Research Patient Engagement Framework.17  67 
Patients were involved in trial governance auditing and provided input on the importance of the 68 
trial outcomes.   69 
 70 
Randomisation and masking 71 
 Patients were randomly assigned (1:1) to accelerated surgery (i.e., goal of surgery within 72 
6 hours of hip fracture diagnosis) or standard care.  Our objective with accelerated surgery was 73 
to facilitate surgery as quickly as possible.  We selected a goal of 6 hours because we knew this 74 
was a substantial improvement beyond standard care and achieving this target was feasible, 75 
based on the HIP ATTACK pilot.  After obtaining consent from the patient or substitute decision 76 
maker, research personnel randomised patients through a central computerised randomisation 77 
system using randomly varying block sizes.  Study personnel and investigators were unaware of 78 
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the block sizes.  Randomisation was stratified by centre and type of planned surgery (i.e., 79 
arthroplasty or open reduction and internal fixation).  Patients, healthcare providers (e.g., 80 
physicians undertaking preoperative medical clearance, anaesthesiologists, surgeons), and study 81 
personnel were aware of patients’ allocated treatment assignment.  Outcome adjudicators were 82 
masked to treatment allocation. 83 
 84 
Procedures 85 
 Patients randomised to accelerated surgery underwent medical clearance by physicians 86 
who were available to rapidly evaluate these patients.  After obtaining medical clearance, these 87 
patients moved into the next orthopaedic elective or trauma operating room slot (i.e., they were 88 
prioritised over elective cases and other non-emergent trauma cases).  Any displaced elective 89 
cases were moved to the subsequent slot and, to avoid cancellation of any moved elective cases, 90 
when needed an extra operating room slot was facilitated at the end of the day.  Patients 91 
randomised to standard care underwent medical clearance and were waitlisted for surgery 92 
according to local standard practices.  All patients in the accelerated-surgery and standard-care 93 
groups underwent medical assessment and clearance before surgery.  The difference between the 94 
groups was that a physician was available to undertake rapid medical assessment of patients in 95 
the accelerated-surgery group, whereas patients in the standard-care group were seen and 96 
medically cleared by a physician according to standard-care timelines (i.e., their medical 97 
assessment was not expedited).   98 
 All patients received the same structured follow-up for outcomes.  For the first 7 days 99 
after randomisation, patients had daily troponin measurements and were assessed for delirium 100 
6 
 
with the confusion assessment method (CAM).18  Patients were followed in hospital and 101 
contacted at 30 and 90 days after randomisation to determine trial outcomes.    102 
 103 
Outcomes and adjudication 104 
The co-primary outcomes were 1.) mortality and 2.) a composite of major complications 105 
(i.e., mortality and non-fatal myocardial infarction, stroke, venous thromboembolism, sepsis, 106 
pneumonia, life-threatening bleeding, and major bleeding) at 90 days after randomisation.  The 107 
Appendix presents secondary and tertiary outcomes and all outcome definitions.  Trained 108 
physicians, masked to the treatment allocation, adjudicated the following outcomes: myocardial 109 
infarction, myocardial injury not fulfilling the definition of myocardial infarction, congestive 110 
heart failure, non-fatal cardiac arrest, stroke, pulmonary embolism, deep vein thrombosis, 111 
pneumonia, sepsis, and bleeding.  Adjudicated events were used for the analyses.  112 
 113 
Trial Monitoring 114 
 Monitoring in HIP ATTACK consisted of central data consistency checks, statistical data 115 
monitoring, and site monitoring.  Site monitoring occurred at hospitals that randomised ≥40 116 
patients or stood out on central data consistency checks or statistical data monitoring.  For site 117 
monitoring, the study statistician randomly selected participants with and without primary 118 
outcomes, and independent monitors audited their hospital charts and supporting documents.  119 
Site monitoring occurred at 26 hospitals that randomised 76% of the trial patients.  Study 120 
personnel corrected any data errors identified through central data consistency checks or site 121 
monitoring.  Central data consistency checks and statistical monitoring raised concerns regarding 122 
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3 centres that had major issues during site monitoring.  Data from these sites (total of 65 patients) 123 
were removed and further details are provided in the Appendix.      124 
 125 
Statistical considerations 126 
 HIP ATTACK was originally designed to randomise 1200 patients, and the primary 127 
outcome was time to a composite of major complications at 30 days of follow-up.  At an 128 
Investigator Meeting in April 2017, without knowledge of the trial results, a decision was made 129 
to increase the sample size to 3000 patients with 2 co-primary outcomes of mortality and a 130 
composite of major complications at 90 days of follow-up.  This increase in sample size was 131 
needed to provide adequate power for the new co-primary outcome of mortality.  For the 132 
comparison of accelerated surgery versus standard care, a sample size of 3000 patients provided 133 
the following: 88% power to detect a hazard ratio (HR) of 0.70 (2-sided α=0.0400) for mortality, 134 
assuming a standard-care group mortality rate of 13%; and 99% power to detect a HR of 0.70 (2-135 
sided α=0.0150) for the composite of major complications, based on 45% overlap between the 136 
two co-primary outcomes and assuming a standard care group major complications rate of 30%.   137 
The Independent Trial Monitoring Committee reviewed the data when 50% of the 138 
patients had completed 30 days of follow-up based on the initial sample size of 1200 patients, 139 
and when 50% and 75% of the patients had completed 90 days of follow-up based on the final 140 
sample size of 3000 patients.  The committee used a modified Haybittle-Peto rule of 4 standard 141 
deviations (SDs) (α=0.0001) for analyses when 50% of the patients had completed follow-up and 142 
3 SDs (α=0.00047) for the analysis when 75% of patients had completed follow-up.            143 
 The Operations Committee wrote and finalized the statistical analysis plan before 144 
analyses were undertaken or any investigators were unmasked to trial results.  Patients were 145 
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analysed in the groups to which they were randomised (i.e., based on the intention-to-treat 146 
principle), regardless of the timing of their surgery.  Patients lost to follow-up without having 147 
had the outcome of interest were censored on the last day their outcome status was known.   148 
For the co-primary outcomes, we used Cox proportional hazards models to estimate the 149 
effect of accelerated surgery versus standard care, with stratification based on the type of 150 
planned surgery (i.e., arthroplasty versus open reduction and internal fixation).  For the co-151 
primary outcomes, we also plotted event rates over time using Kaplan-Meier methodology and 152 
used the log-rank test to determine p values.   153 
The co-primary analyses were based on a fallback procedure such that if the first co-154 
primary outcome (i.e., time to death) was significant at α=0.0400, then the alpha would be 155 
unused and passed to the second co-primary outcome (i.e., time to a major complication), which 156 
would then be evaluated at α=0.05.19  If the first co-primary outcome was found to be non-157 
significant, the second co-primary outcome would be evaluated at α=0.0150.  With the fallback 158 
hierarchical testing procedure, the type I error rate is partitioned among the co-primary outcomes 159 
in an order determined a priori; if the first hypothesis is rejected, the type I error rate can be 160 
accumulated, thus preserving the family-wise type I error rate.19 161 
 Secondary and tertiary binary events with an event date were analysed using an approach 162 
similar to that of the primary outcomes.  For secondary and tertiary outcomes that were binary 163 
events but without an event date (e.g., new residence in a nursing home), logistic regression was 164 
undertaken to estimate the effect of accelerated surgery versus standard care, and a χ2 test was 165 
used to calculate the p value.   166 
 For the co-primary outcomes, we performed the following 2 prespecified subgroup 167 
analyses: 1.) patients who presented to the hospital <4 hours after their hip fracture, ≥4-24 hours 168 
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after their hip fracture, versus >24 hours after their hip fracture; and 2.) patients who had, versus 169 
did not have, an acute severe medical condition (Appendix) after their hip fracture but before 170 
randomisation.  We expected a larger relative treatment effect in patients who presented earlier 171 
after their fracture and a smaller treatment effect in patients who had acute severe medical 172 
conditions after their fracture but before randomisation.  We used Cox proportional hazards 173 
models that incorporated tests of interaction, designated as significant if p<0.05. 174 
 All analyses were performed in SAS®, version 9.4.  This trial was registered with 175 
ClinicalTrials.gov, number NCT02027896.   176 
 177 
Trial coordination and role of the funding sources 178 
 The study was funded by grants from the CIHR, the Ontario Strategy for Patient Oriented 179 
Research Support Unit, the Ontario Ministry of Health and Long-Term Care, the Hamilton 180 
Health Sciences Foundation, Physicians’ Services Incorporated Foundation, Michael G. 181 
DeGroote Institute for Pain Research and Care, Smith & Nephew (to recruit patients in Spain), 182 
and Indiegogo Crowdfunding.  The Population Health Research Institute was the trial 183 
coordinating centre and was responsible for the randomisation system, maintenance of the 184 
database, data monitoring, analyses, and study-centre coordination.  The funders of the trial had 185 
no role in data collection, data analyses, data interpretation, or writing of the manuscript.  The 186 
corresponding author had full access to all of the data and had final responsibility for the 187 
decision to submit for publication.  188 
 189 
RESULTS 190 
10 
 
 We randomised 2970 patients to receive accelerated surgery (n=1487) or standard care 191 
(n=1483).  Fifteen patients (<1%) were lost to follow-up after hospital discharge (Figure 1).  The 192 
baseline characteristics and details of surgery were similar between groups (Table 1).  Among 193 
participants, the mean age was 79 years, 69% were women, 33% needed help with activities of 194 
daily living, 22% had diabetes, 18% had dementia, and 18% resided in a nursing home before 195 
their hip fracture.  The most common types of fractures were intertrochanteric (52%) and 196 
femoral neck (44%).  The surgeries performed were open reduction and internal fixation in 63% 197 
of participants and arthroplasty in 35%.   198 
 The timelines from hip fracture to randomisation were similar between the 2 groups 199 
(Table 2).  The median time from hip fracture to hospital arrival was 3 hours (interquartile range 200 
[IQR], 1-15), and the median time from hospital arrival to randomisation was 3 hours (IQR, 2-5).  201 
The median time from hip fracture diagnosis to medical clearance was 2 hours (IQR, 1-4) in the 202 
accelerated-care group and 4 hours (IQR, 2-13) in the standard-care group, p<0.0001.  The 203 
median time from hip fracture diagnosis to surgery was 6 hours (IQR, 4-9) in the accelerated-204 
surgery group and 24 hours (IQR, 10-42) in the standard-care group; median absolute difference 205 
of 18 hours (95% confidence interval [CI] 17-19), p<0.0001.   206 
Death occurred in 140 patients (9%) assigned to accelerated surgery and 154 patients 207 
(10%) assigned to standard care; HR 0.91, 95% CI 0.72-1.14; absolute risk reduction (ARR) 1%, 208 
95% CI -1-3%; p=0.40, (Table 3, Figure 2).  A major complication occurred in 321 patients 209 
(22%) randomised to accelerated surgery and 331 patients (22%) randomised to standard care; 210 
HR 0.97, 95% CI 0.83-1.13; ARR 1%, 95% CI -2-3%; p=0.71.  Post-hoc random-effects Cox 211 
models that adjusted for potential site-clustering effects produced similar results to the primary 212 
analyses (Supplemental Table 1).    213 
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Among the secondary outcomes, there were fewer strokes in patients randomised to 214 
accelerated surgery compared to standard care (5 patients [<1%] versus 14 patients [1%]; HR 215 
0.35, 95% CI 0.13-0.97; p=0.0470) (Table 3).  Post-hoc Fisher’s exact test for stroke 216 
demonstrated p=0.0405.  Delirium was less common in the accelerated-surgery group (132 217 
patients [9%]) compared to the standard-care group (175 patients [12%]), odds ratio (OR) 0.72, 218 
(95% CI 0.58-0.92); ARR 3%, 95% CI 1-5%.  Fewer patients randomised to accelerated surgery 219 
compared to standard care had an infection without sepsis (170 patients [11%] versus 207 220 
patients [14%]; HR 0.80, 95% CI 0.65-0.98).  Fewer patients had a urinary tract infection in the 221 
accelerated-surgery group compared to the standard-care group (120 patients [8%] versus 150 222 
patients [10%]; HR 0.78, 95% CI 0.61-0.99; ARR 2%, 95% CI <1-4%) (Supplemental Table 2).     223 
 For the tertiary clinical outcomes, including 5 orthopaedic outcomes (i.e., hip re-224 
operation, prosthetic hip dislocation, implant failure, peri-prosthetic fracture, and surgical site 225 
infection), there were no significant differences between the randomised groups (Supplemental 226 
Table 3).  Patients allocated to accelerated care were faster to mobilise after randomisation 227 
compared to patients allocated to standard care (25 hours [IQR, 21-45] versus 46 hours [IQR, 31-228 
71]; absolute median difference 21 hours; 95% CI 20-22; p<0.0001) (Supplemental Table 4).  229 
The mean time from randomisation to hospital discharge was 10 days in the accelerated-surgery 230 
group and 11 days in the standard-care group; absolute mean difference 1 day (95% CI 1-2; 231 
p<0.0001).   232 
Patients randomised to accelerated surgery stood up and were able to fully weight bear 233 
earlier than patients randomised to standard care (absolute median difference 21 hours, 95% CI 234 
18-24; and 26 hours, 95% CI 21-30, respectively) (Supplemental Table 5).  Post-hoc analyses 235 
demonstrated that more patients randomised to accelerated care were discharged ≤10 days after 236 
12 
 
randomisation, whereas more patients randomised to standard care stayed 11-20 days and >20 237 
days from randomisation to hospital discharge (Supplemental Table 6).   238 
 The effects on mortality did not differ across the prespecified subgroups (Figure 3).  For 239 
the co-primary outcome of major complications, the subgroup analysis based on time from hip 240 
fracture to hospital arrival demonstrated a significant interaction (p=0.0198).  This subgroup 241 
analysis demonstrated that the HR for major complications decreased as the time from hip 242 
fracture to hospital arrival increased.   243 
 Subgroup analyses for the co-primary outcomes based on an expanded list of acute 244 
medical conditions (Appendix), broader than the pre-specified subgroup, demonstrated the 245 
effects were consistent across the subgroups (Supplemental Figure 1).  Post-hoc subgroup 246 
analyses for the co-primary outcomes based on whether patients had an elevated troponin 247 
measurement before randomisation demonstrated a statistically significant interaction (p=0.0076) 248 
for mortality (Supplemental Figure 2).  These analyses suggested patients with an elevated 249 
troponin measurement at baseline had a lower risk of mortality with accelerated surgery 250 
compared to standard care (17 deaths among 174 accelerated-surgery patients [10%] versus 42 251 
deaths among 175 standard-care patients [24%]; HR 0.38, 95% CI 0.21-0.66).       252 
 Post-hoc subgroup analyses for the co-primary outcomes, based on the type of fracture 253 
(i.e., intertrochanteric versus femoral neck) and separately based on the type of surgery (open 254 
reduction and internal fixation versus arthroplasty), demonstrated that the effects were consistent 255 
across the subgroups (Supplemental Figure 3 and 4, respectively).  Post-hoc analyses for the co-256 
primary outcomes based on patients’ age (i.e., 45-64, 65-84, and ≥85 years) demonstrated the 257 
effects were consistent across the subgroups (Supplemental Figure 5).    258 
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The day after randomisation, patients in the accelerated-surgery group had a lower pain 259 
score than patients in the standard-care group (Supplemental Table 7).  Fewer patients in the 260 
accelerated-care group had moderate to severe pain on days 4-7 after randomisation, compared to 261 
patients in the standard-care group (Supplemental Table 8).     262 
 263 
DISCUSSION 264 
Statement of principal findings 265 
 Accelerated surgery did not reduce the risk of the co-primary outcomes of mortality and a 266 
composite of major complications, compared to standard care.  Accelerated surgery compared to 267 
standard care resulted in a lower risk of delirium (OR 0.72, 95% CI 0.58-0.92), urinary tract 268 
infection (HR 0.78, 95% CI 0.61-0.99), and moderate to severe pain on days 4-7 after 269 
randomisation.  Accelerated surgery also resulted in faster mobilisation after randomisation 270 
(absolute median difference, 21 hours; 95% CI 20-22), and a shorter time from randomisation to 271 
hospital discharge (absolute mean difference, 1 day; 95% CI 1-2).   272 
 273 
Our trial in relation to other studies 274 
A systematic review and meta-analysis of risk-adjusted observational data demonstrated, 275 
irrespective of the cut-off defining delayed surgery (24, 48, or 72 hours), earlier surgery (i.e., 276 
within the cut-off time) was associated with a significantly lower risk of mortality (4208 patients, 277 
721 deaths; relative risk 0.81, 95% CI 0.68–0.96).10  Risk adjusted observational studies have 278 
demonstrated that surgery within 12 hours of a hip fracture diagnosis was associated with a 279 
lower risk of mortality.11,20,21  Although these observational studies undertook risk-adjusted 280 
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analyses, observational studies remain at risk of confounding by indication and residual 281 
confounding.       282 
Two small trials randomised patients with a hip fracture to accelerated surgery versus 283 
standard care.  One trial randomised 71 patients with a hip fracture to early surgery or standard 284 
care; median time to surgery was 1 day versus 2 days, respectively.22  The investigators reported 285 
that patients allocated to early surgery had a shorter length of hospital stay compared to patients 286 
allocated to standard care (21 versus 33 days; relative risk [RR] 0.48, 95% CI 0.27-0.85).  HIP 287 
ATTACK also showed that accelerated surgery had a reduced time from randomisation to 288 
hospital discharge.  The HIP ATTACK pilot randomised 60 patients to accelerated surgery or 289 
standard care with median times from diagnosis to surgery of 6 versus 24 hours, respectively.7  290 
In this pilot 4 patients randomised to accelerated surgery and 9 patients randomised to standard 291 
care developed delirium.  These results were consistent with the HIP ATTACK trial.  292 
 293 
Interpretation 294 
 Despite surgery being performed at a median time of 6 hours after the hip fracture 295 
diagnosis in the accelerated-surgery group versus a median of 24 hours in the standard-care 296 
group (median absolute difference of 18 hours, 95% CI 17-19), there was no significant effect of 297 
accelerated surgery on mortality (HR 0.91, 95% CI 0.72-1.14) or major complications (HR 0.97, 298 
95% CI 0.83-1.13).  Accelerated surgery did, however, demonstrate a reduction in delirium (OR 299 
0.72, 95% CI 0.58-0.92, ARR 3%, 95% CI 1-5%), urinary tract infection (HR 0.78, 95% CI 0.61-300 
0.99, ARR 2%, 95% CI, <1-4%), and moderate to severe pain on days 4-7 after randomisation.  301 
The ARR for delirium and urinary tract infection represent effects that patients are likely to 302 
consider important.   303 
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Accelerated surgery may have reduced the risk of delirium by reducing urinary tract 304 
infection, reducing moderate to severe pain, and having patients mobilise, stand, and weight bear 305 
more rapidly than patients randomised to standard care.  In patients presenting with a hip 306 
fracture, to avoid the discomfort associated with using a bedpan to urinate, it is common practice 307 
to insert a Foley catheter.  These catheters are usually not removed until after surgery, when 308 
patients start to mobilise.  That patients randomised to accelerated surgery underwent surgery 18 309 
hours earlier and mobilised 21 hours earlier than patients randomised to standard care may 310 
explain how accelerated surgery reduced the risk of urinary tract infection.  Although patients 311 
allocated to accelerated surgery demonstrated a lower risk of stroke, we offer cautious 312 
interpretation of this finding.  In contrast to delirium (307 events) and urinary tract infection (270 313 
events), there were only 19 strokes and this result has a fragility index of 2 (i.e., only 2 patients 314 
in the accelerated-care group would have to change from not having a stroke to having a stroke 315 
to reverse statistical significance).23   316 
The mean time from randomisation to hospital discharge was 10 days in the accelerated-317 
surgery group and 11 days in the standard-care group; absolute mean difference 1 day (95% CI 318 
1-2; p<0.0001).  Given the cost associated with spending an extra day in the hospital, this 319 
represents an important difference.  Several points support the credibility of this finding: 1.) the 320 
coherence of the data across outcomes – patients randomised to accelerated surgery had surgery 321 
18 hours earlier, mobilized 21 hours earlier, stood 21 hours earlier, and achieved full weight 322 
bearing 26 hours earlier, compared to patients randomised to standard care; one would anticipate 323 
that patients who mobilize, stand, and weight bear more quickly will also be discharged earlier; 324 
2.) more patients randomised to accelerated care were discharged ≤10 days after randomisation, 325 
whereas more patients randomised to standard care stayed 11-20 days and >20 days from 326 
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randomisation to hospital discharge (Supplemental Table 6); and 3.) prior data from a small trial 327 
supports this finding.22  Of our two a priori subgroup analyses, one demonstrated a statistically 328 
significant interaction p value (i.e., for the composite outcome based on time from hip fracture to 329 
hospital arrival) (Figure 3).  Although a significant interaction p value suggests the differences in 330 
treatment effects are beyond what would be expected based on chance and supports the 331 
credibility of a subgroup effect, the observed direction of effect was the opposite of our stated a 332 
priori hypothesis (i.e., we expected a larger treatment effect in patients who present within 333 
shorter time periods of their hip fracture, whereas we observed the opposite), which substantially 334 
lowers the credibility that this represents a real subgroup effect.24,25   335 
Some authors have cautioned that accelerated surgery for a hip fracture may negatively 336 
impact patients’ outcomes by preventing or limiting the opportunity to optimize patients’ 337 
medical conditions before surgery;26,27 however, our subgroup analysis based on acute medical 338 
conditions does not support this concern (Figure 3, Supplemental Figure 4).  Moreover, our post-339 
hoc subgroup analysis suggested patients with an elevated troponin measurement at baseline had 340 
a lower risk of mortality with accelerated surgery compared to standard care (HR 0.38, 95% CI 341 
0.21-0.66).  An elevated baseline troponin measurement in patients with a hip fracture may 342 
identify patients who are not tolerating the physiological stress associated with the hip fracture, 343 
and these patients may benefit from accelerated surgery.   344 
Waiting for hip fracture surgery is undesirable.  When patients sustain a hip fracture, they 345 
are forced to lie flat in a bed and are either in pain or needing analgesic medications, which often 346 
have side effects.  Moreover, patients usually have to fast while waiting for surgery and many 347 
will get a urinary catheter, which will only be removed after surgery.  That <5% of eligible 348 
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patients declined to participate in the HIP ATTACK trial provides evidence that patients want 349 
accelerated surgery.   350 
HIP ATTACK further provides evidence of the safety and benefits (e.g., reduced risk of 351 
delirium and more rapid mobilisation) of accelerated surgery compared to standard care.  Lack of 352 
operating room time and medical clearance are the main barriers to accelerated surgery.28,29  We 353 
demonstrated in HIP ATTACK that it is possible to overcome these barriers.  Patients 354 
randomised to accelerated surgery went into the next orthopaedic elective or trauma operating 355 
room slot and any displaced elective cases were moved to the subsequent slot.  To avoid 356 
cancelling any elective cases, when needed, an extra operating room slot was facilitated at the 357 
end of the day.  This represents the main cost to centres to facilitate accelerated surgery.  This 358 
cost along with the cost savings from discharging a patient home a day earlier will help inform 359 
the economics of accelerated surgery.  We plan to publish formal economic analyses related to 360 
the HIP ATTACK data.  Moreover, we will publish the 1-year results, after all patients have 361 
completed the 1-year follow-up. 362 
 HIP ATTACK included patients ≥45 years of age, and the trial does not inform the effect 363 
of accelerated surgery on younger patients.  Patients <45 years of age are, however, commonly 364 
excluded from perioperative trials because of their lower risk of postoperative complications.30-32  365 
Moreover, it is uncommon for patients <45 years of age to suffer a low-energy mechanism hip 366 
fracture. 367 
 368 
Strengths and limitations 369 
 HIP ATTACK is the first large randomised trial to inform the effects of accelerated 370 
surgery compared to standard care.  We obtained follow-up on >99% of participants.  HIP 371 
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ATTACK has limitations.  Three centres had major data quality issues, and we had to remove 372 
these centres and their 65 randomised patients from the trial.  Although this resulted in our trial 373 
falling just short of our intended sample size (i.e., 2970 patients instead of 3000), this did not 374 
have a meaningful impact on power.  Despite variation in the time from hip fracture diagnosis to 375 
surgery in our standard-care group, our results primarily inform the effects for patients who went 376 
to surgery a median of 6 versus 24 hours after their hip fracture was diagnosed.  Observational 377 
data, clinical experience, and biological rationale suggest that the longer a patient is immobile 378 
and lying in a bed the higher the risk of poor outcomes.2  Therefore, our findings do not preclude 379 
different results in centres with standards of care that take substantially longer to get patients into 380 
surgery than the standard-care group in HIP ATTACK.   381 
We did not collect data on the orthopaedic outcomes of non-union or malunion; however, 382 
accelerated surgery had no effect on the 5 orthopaedic outcomes we did evaluate (Supplemental 383 
Table 3).  We did not collect data on the timing of urinary catheter removal following surgery.  384 
We expected a standard-care group mortality rate of 13% but it was 10% and a major 385 
complications rate of 30% but it was 22%.  Considering the 95% CIs around their associated 386 
treatment effects, there is still the possibility of a 28% relative risk reduction (RRR) for mortality 387 
and a 17% RRR for major complication.  We only included patients diagnosed during regular 388 
working hours.  Given that after regular working hours, there tend to be fewer healthcare 389 
providers in hospitals and those providers may be more fatigued, understanding the effects of 390 
accelerated surgery outside of regular working hours will require its own trial.  We did not 391 
collect data on the seniority of surgeons, anaesthesiologists, and physicians.  Although physician 392 
skill level may vary across sites and may affect outcomes, randomisation was stratified by centre 393 
to minimize any such impact on the effects of the study treatment groups.          394 
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 395 
Conclusions 396 
 Among patients with a hip fracture, accelerated surgery did not lower the risk of 397 
mortality or a composite of major complications compared to standard care.  It did, however, 398 
reduce the risk of delirium, urinary tract infection, and moderate to severe pain, and resulted in 399 
faster mobilisation, standing, weight bearing, and hospital discharge.    400 
  401 
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